Cassava Sciences, Inc. - Common Stock (SAVA)
2.3800
+0.00 (0.00%)
NASDAQ · Last Trade: Dec 23rd, 8:40 AM EST
FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.
Via Stocktwits · December 19, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · December 19, 2025
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · November 24, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via Chartmill · September 25, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · September 24, 2025
Cassava Sciences (NASDAQ: SAVA) witnessed a dramatic surge in its stock price today, climbing an impressive 18% after its President and CEO, Richard Barry, disclosed a significant personal investment in the company. The move, which saw Barry acquire hundreds of thousands of shares, has injected a much-needed dose of confidence
Via MarketMinute · September 23, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · September 23, 2025
Via Benzinga · September 23, 2025
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · September 23, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · September 23, 2025
Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each.
Via Benzinga · September 23, 2025
Via Benzinga · September 23, 2025
Via Benzinga · September 23, 2025
Via Benzinga · September 22, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · September 22, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · March 25, 2025
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025.
Via Stocktwits · March 25, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · March 25, 2025
Via Benzinga · March 25, 2025
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
Via Benzinga · March 25, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · March 25, 2025

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.
Via Benzinga · March 3, 2025
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.
Via Talk Markets · December 12, 2024
